Oxford Pooling Project: Prostate (endogenous hormones and nutritional biomarkers):Updated
Principal Investigator
Name
Amanda Black
Degrees
Ph.D, M.P.H
Institution
NCI
Position Title
Associate Director
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-350
Initial CDAS Request Approval
Mar 2, 2018
Title
Oxford Pooling Project: Prostate (endogenous hormones and nutritional biomarkers):Updated
Summary
The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (EHNPCCG) was established in 2004, with the aim of collating the worldwide prospective data and to perform collaborative re-analyses on the relationship between circulating sex hormones, nutritional biomarkers and prostate cancer risk. The first results (based on almost 4,000 cases) were published in 2008 showing no association between circulating sex hormones and prostate cancer risk. An increased risk of prostate cancer was observed with increasing levels of IGF-I. Since then, approximately double the cases have become available worldwide. PLCO was not included in the earliest analyses but has since published on hormones and prostate cancer risk. Further, PLCO has also published on the association between multiple analytes and prostate cancer risk of interest to the group. EHNPCCG has invited PLCO to participate in a new effort to update the information on sex hormones and IGFs in relation to prostate cancer and to include new data on nutritional biomarkers. The aim of this pooling project is to provide a unified analysis of the published worldwide prospective data to further our understanding of the relationships of endogenous hormones and nutritional biomarkers with risk of prostate cancer and prostate cancer-specific mortality. To date, PLCO has published on the relationship between prostate cancer and hormones and nutritional biomarkers (including testosterone, estrogens and metabolites, IGF-I, SHBG, carotenoids, tocopherols, retinol, vitamin D, alanine, sarcosine, total cholesterol, and selenium). We request permission to participate in this collaborative effort and to share these published data with the EHNPCCG and to include vital status.
Aims
The aims of pooling the data are to:
1. Use uniform methods to provide more precise estimates of the relative risks for each individual biomarker.
2. Investigate the relationship of time between blood collection and diagnosis with risk.
3. Identify which biomarker is most closely associated with risk by allowing the biomarkers to be mutually adjusted.
4. Examine the relationships between subject characteristics and biomarker concentrations in a cross-sectional manner.
5. Examine the relative risks in subgroups by stage and grade of the cancer and other factors (e.g. diabetes), as appropriate
Collaborators
Dr Michael Cook, DCEG
University of Oxford